

Corporate Office:
Torrent House,
Off Ashram Road,
Ahmedabad-380 009,
India.

Phone : (079) 26585090 /
26583060

Fax : (079) 26582100

23rd July, 2012

The Dy. General Manager (Listing Dept.)
Bombay Stock Exchange Limited
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Audited Financial Results and Unaudited Consolidated Financial Results for the Quarter ended on 30th June, 2012.

We enclose herewith the following:

1. 'Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with the limited review report of the Company for the quarter ended on 30th June, 2012 as per clause 41 of the Listing Agreement, which were approved by the Board of Directors at its meeting held on 23rd July, 2012.

In terms of clause 41(VI) (b) of the Listing Agreement, the Company will publish above Unaudited Consolidated Financial Results for the quarter ended 30th June, 2012. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com.

2. Press Release on Financial Results as being submitted to the press media.

The above is for your information and record.

Thanking you,

Yours faithfully,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
SVP (LEGAL) & COMPANY SECRETARY

Encl.: A/a

AUDITORS' REPORT TO THE BOARD OF DIRECTORS OF TORRENT PHARMACEUTICALS LIMITED

1. We have audited the accompanying Statement of Financial Results ("the Statement") of **TORRENT PHARMACEUTICALS LIMITED** ("the Company") for the quarter ended 30th June, 2012, being submitted by the Company pursuant to Clause 41 of the Listing Agreements with the Stock Exchanges. This Statement has been prepared on the basis of the related interim financial statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express an opinion on the Statement, based on our audit of the related interim financial statement, which has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS-25) on Interim Financial Reporting notified under the Companies (Accounting Standards) Rules, 2006 and other accounting principles generally accepted in India.
2. We conducted our audit of the Statement in accordance with the auditing standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the Statement is free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts and the disclosures in the Statement. An audit also includes assessing the accounting principles used and the significant estimates made by the Management, as well as evaluating the overall Statement presentation. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) is presented in accordance with the requirements of Clause 41 of the Listing Agreements with the Stock Exchanges and
 - (ii) gives a true and fair view of the net profit and other financial information of the Company for the quarter ended 30th June, 2012.

[Handwritten signature]


Deloitte Haskins & Sells

Deloitte Haskins & Sells
Chartered Accountants
'Heritage', 3rd Floor,
Near Gujarat Vidhyapeeth,
Off Ashram Road,
Ahmedabad - 380 014.

Tel: +91 (079) 27582542
+91 (079) 27582543
+91 (079) 66073100
Fax: +91 (079) 27582551

4. Further, we also report that we have traced from the details furnished by the Management, the number of shares as well as the percentage of shareholdings in respect of the aggregate amount of public shareholdings and the number of shares as well as the percentage of shares pledged/encumbered in respect of the aggregate amount of promoter and promoter group in terms of Clause 35 of the Listing Agreements and the particulars relating to the undisputed investor complaints.

For DELOITTE HASKINS & SELLS
Chartered Accountants
(Registration No. 117365W)



(Gaurav J. Shah)
Partner


Membership No. 35701

Place: Ahmedabad

Date: 23rd July, 2012

TORRENT PHARMACEUTICALS LIMITED

PART I		[Rs. in Lacs except per share data]			
Statement of Standalone Audited Results for the Quarter Ended 30-Jun-2012					
Particulars	Quarter ended			Year ended	
	30-Jun-2012	31-Mar-2012	30-Jun-2011	31-Mar-2012	
Income from operations					
Net sales (Net of excise duty) (see note 2)	62011	52657	47802	198669	
Other operating income	2899	1802	2881	8935	
Total income from operations (net)	64910	54459	50683	207604	
Expenses					
Cost of materials consumed	17606	14749	14739	59017	
Purchases of stock-in-trade	11992	8329	2911	25210	
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(4879)	515	(368)	(3596)	
Employee benefits expense	8803	7868	7753	30905	
Depreciation and amortisation expense	1632	1676	1468	6390	
Other expenses	17022	16484	11937	56029	
Total expenses	52176	49621	38440	173955	
Profit from operations before other income, finance costs and exceptional items	12734	4838	12243	33649	
Other income	5790	9925	1286	13519	
Profit from ordinary activities before finance costs and exceptional items	18524	14763	13529	47168	
Finance costs	1043	936	1020	3978	
Profit from ordinary activities after finance costs but before exceptional items	17481	13827	12509	43190	
Exceptional items	-	6120	-	6120	
Profit from ordinary activities before tax	17481	7707	12509	37070	
Tax expense	2729	(300)	2565	5945	
Net profit for the period	14752	8007	9944	31125	
Paid-up equity share capital (Face value of Rs.5 each)	4231	4231	4231	4231	
Reserves excluding revaluation reserves	-	-	-	126218	
Earnings per share (of Rs. 5/- each) (not annualised):					
Basic	17.44	9.46	11.75	36.79	
Diluted	17.44	9.46	11.75	36.79	





PART II				
Select Information for the Quarter Ended 30-Jun-2012				
PARTICULARS OF SHAREHOLDING		Quarter ended		
		30-Jun-2012	31-Mar-2012	30-Jun-2011
Public shareholding	- Number of shares	24109500	24109500	24109500
	- Percentage of shareholding	28.49%	28.49%	28.49%
Promoters and Promoter group Shareholding	a) Pledged/Encumbered	Nil	Nil	Nil
	- Number of shares	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil
	- Percentage of shares (as a % of the total capital of the company)	Nil	Nil	Nil
b) Non-encumbered	- Number of shares	60501860	60501860	60501860
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%
	- Percentage of shares (as a % of the total capital of the company)	71.51%	71.51%	71.51%
INVESTOR COMPLAINTS		Quarter ended 30-Jun-2012		
Pending at the beginning of the quarter		Nil	Nil	Nil
Received during the quarter		Nil	Nil	Nil
Disposed of during the quarter		Nil	Nil	Nil
Remaining unresolved at the end of the quarter		Nil	Nil	Nil

Notes:

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 23-July-2012. There is no qualification in the Auditors Report on this statement of financial results.
- 2 The Company operates a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

[Rs. in Lacs]

Particulars	Quarter ended			Year ended
	30-Jun-2012	30-Jun-2011	Growth %	31-Mar-2012
(A) Sales in India				
Branded sales	28023	24643	14%	91670
Contract manufacture	4751	6133	(23%)	24271
Others	351	123	-	1472
Total sales in India	33125	30899	7%	117413
(B) Sales outside India	29057	16997	71%	81736
Total sales (A+B)	62182	47896	30%	199149
Less: Excise duty	171	94	-	480
Net sales	62011	47802	30%	198669

- 3 During the current quarter, the Company made additional investment of Rs. 1520 lacs, in equity shares of its wholly owned subsidiary, Zao Torrent Pharma.
- 4 The Company has also prepared and published unaudited consolidated financial results for the quarter ended 30-Jun-2012, which were subjected to limited review by statutory auditors of the Company.



For TORRENT PHARMACEUTICALS LIMITED

[Signature]

SAMIR MEHTA

Executive Vice Chairman

Place : Ahmedabad

Date : 23-Jul-2012

.... Visit us at www.torrentpharma.com....

**AUDITORS' REPORT
TO THE BOARD OF DIRECTORS OF
TORRENT PHARMACEUTICALS LIMITED**

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results ("the Statement") of **TORRENT PHARMACEUTICALS LIMITED** ("the Company"), its subsidiaries (the Company and its subsidiaries constitute "the Group") for the quarter ended 30th June, 2012. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an opinion.
3. The Statement includes the results of the following subsidiaries:

(1) Zao Torrent Pharma, (2) Torrent Pharma GmbH, (3) Heumann Pharma GmbH & Co. Generica KG, (4) Torrent Do Brasil Ltda, (5) Torrent Pharma Philippines Inc., (6) Torrent Pharma Inc., (7) Laboratories Torrent S.A. de C.V., (8) Torrent Australasia Pty Ltd., (9) Heunet Pharma GmbH, (10) Norispharm GmbH, (11) Torrent Pharma Canada Inc., (12) Torrent Pharma (Thailand) Co., Limited, (13) Torrent Pharma S.R.L., (14) Torrent Pharma (UK) Limited, (15) Torrent Pharmaceuticals (Dahej), (16) Torrent Pharmaceuticals (Sikkim) and (17) Laboratories Torrent (Malaysia) Sdn. Bhd.
4. Based on our review, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the Accounting Standards referred to in Section 211 (3C) of the Companies Act, 1956 and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the stock exchanges, including the manner in which it is to be disclosed, or that it contains any material misstatement.

SRS


Deloitte Haskins & Sells

Deloitte Haskins & Sells
Chartered Accountants
'Heritage', 3rd Floor,
Near Gujarat Vidhyapeeth,
Off Ashram Road,
Ahmedabad - 380 014.

Tel: +91 (079) 27582542
+91 (079) 27582543
+91 (079) 66073100
Fax: +91 (079) 27582551

5. Further, we also report that we have traced from the details furnished by the Management, the number of shares as well as the percentage of shareholdings in respect of the aggregate amount of public shareholdings and the number of shares as well as the percentage of shares pledged/encumbered in respect of the aggregate amount of promoter and promoter group in terms of Clause 35 of the Listing Agreements and the particulars relating to the undisputed investor complaints.

For DELOITTE HASKINS & SELLS
Chartered Accountants
(Registration No. 117365W)



(Gaurav J. Shah)
Partner


Membership No. 35701

Place: Ahmedabad


Date: 23rd July, 2013

TORRENT PHARMACEUTICALS LIMITED

PART I		[Rs. in Lacs except per share data]		
Statement of Consolidated Results for the Quarter Ended 30-Jun-2012				
Particulars	Quarter ended (Unaudited)			Year ended (Audited)
	30-Jun-2012	31-Mar-2012	30-Jun-2011	31-Mar-2012
Income from operations				
Net sales (Net of excise duty) (see note 3)	73560	65400	61098	259441
Other operating income	3131	2033	3121	10151
Total income from operations (net)	76691	67433	64219	269592
Expenses				
Cost of materials consumed	20292	17011	15630	65118
Purchases of stock-in-trade	6444	4274	5434	21534
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(4740)	998	(1474)	(340)
Employee benefits expense	15306	14424	12587	53372
Depreciation and amortisation expense	2013	2177	2019	8173
Other expenses	23793	22222	17015	79843
Total expenses	63108	61106	51211	227700
Profit from operations before other income, finance costs and exceptional items	13583	6327	13008	41892
Other income	1402	1243	1147	4451
Profit from ordinary activities before finance costs and exceptional items	14985	7570	14155	46343
Finance costs	942	894	1022	3945
Profit from ordinary activities after finance costs but before exceptional items	14043	6676	13133	42398
Exceptional item	-	6536	-	6536
Profit from ordinary activities before tax	14043	140	13133	35862
Tax expense	3739	237	2874	7232
Net Profit / (Loss) for the period	10304	(97)	10259	28630
Minority Interest	119	68	7	226
Net Profit / (Loss) after taxes and minority interest	10185	(165)	10252	28404
Paid-up equity share capital (Face value of Rs. 5 each)	4231	4231	4231	4231
Reserves excluding Revaluation Reserves				115151
Earnings per share (of Rs. 5/- each) (not annualised):				
Basic	12.04	(0.20)	12.12	33.57
Diluted	12.04	(0.20)	12.12	33.57



PART II				
Select Information for the Quarter Ended on 30-Jun-2012				
PARTICULARS OF SHAREHOLDING	Quarter ended			Year ended
	30-Jun-2012	31-Mar-2012	30-Jun-2011	31-Mar-2012
Public shareholding				
- Number of shares	24109500	24109500	24109500	24109500
- Percentage of shareholding	28.49%	28.49%	28.49%	28.49%
Promoters and Promoter Group Shareholding				
(a) Pledged / Encumbered				
- Number of shares	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil
(b) Non - encumbered				
- Number of shares	60501860	60501860	60501860	60501860
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	71.51%	71.51%	71.51%	71.51%
INVESTOR COMPLAINTS	Quarter ended			
	30-Jun-2012			
Pending at the beginning of the quarter	Nil			
Received during the quarter	Nil			
Disposed of during the quarter	Nil			
Remaining unresolved at the end of the quarter	Nil			



Notes:

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 23-Jul-2012.
- 2 The statement of financial results consolidate the financial results of fifteen wholly owned subsidiaries and two partnership firms with that of the Company.
- 3 The Company operates a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

[Rs. in Lacs]

Particulars	Quarter ended (Unaudited)			Year ended (Audited)
	30-Jun-2012	30-Jun-2011	Growth %	31-Mar-2012
(A) Sales in India				
Branded sales	28023	24643	14%	91670
Contract manufacture	4751	6133	(23%)	24271
Others	252	59	-	658
Total sales in India	33026	30835	7%	116599
(B) Sales outside India	40705	30357	34%	143322
Total sales (A+B)	73731	61192	20%	259921
Less: Excise duty	171	94	-	480
Net sales	73560	61098	20%	259441

- 4 Summary details of stand-alone audited financial results of Torrent Pharmaceuticals Limited :


Particulars	Quarter ended			Year ended
	30-Jun-2012	31-Mar-2012	30-Jun-2011	31-Mar-2012
Net sales & operating income	64910	54459	50683	207604
Profit before tax	17481	7707	12509	37070
Profit after tax	14752	8007	9944	31125

- 5 The figures for the comparative periods have been regrouped, wherever necessary, to make them comparable with the figures for the current periods.
- 6 The stand-alone audited financial results for the quarter ended 30-Jun-2012 are available on the Company's website at www.torrentpharma.com.

Place : Ahmedabad
Date : 23-Jul-2012



For TORRENT PHARMACEUTICALS LIMITED


SAMIR MEHTA
Executive Vice Chairman

.... Visit us at www.torrentpharma.com....

Torrent Pharma records 19% growth in Revenues during Q1 12-13

Ahmedabad-based Torrent Pharmaceuticals Limited, today released its financial results for the quarter ended 30th June, 2012. The Q1'12-13 revenues stood at Rs. 767 crores, up by 19% from Rs. 642 crores in the comparable quarter of last year.

During Q1, domestic formulation business recorded revenues of Rs. 279 crores, growing by 14%. International revenues grew by 33% to Rs. 422 crores. Operations in Brazil registered revenue growth of 26%. Revenues from the US operations recorded growth of 78% while business from Europe (other than Heumann), Russia & CIS and Rest of the World recorded a growth of 40%.

Operating profits (PBDIT) for the quarter stood at Rs. 156 crores showing a growth of 4%. Brazil base effect was the main factor leading to lower growth in operating profits. Net profit before Taxes for the quarter grew by 7% to Rs. 140 crores compared to Rs. 131 crores during the same period last year.

The total revenue expenditure on R&D was 4% of consolidated net sales and operating income.

About Torrent Pharma: Torrent Pharma, with an annual turnover of over Rs. 2,650 crores is the flagship company of the Torrent Group. With many of its products ranking among the Top 200 brands, Torrent continues to be at the forefront of the Indian pharmaceutical industry through research, innovation and breakthrough discoveries in the therapeutics areas of Diabetology, Cardiovascular, Central Nervous System, Gastro-Intestinal, Anti-infective, Pain management and Gynecology. Its Research Center employs over 640 scientists in the areas of drug discovery and development. Currently, Torrent has various discovery projects in pipeline. It has filed 450 patents for NCE's in all major markets worldwide, of which 211 patents have been granted so far. Torrent's manufacturing plant at Chhatral has a capacity to manufacture approx. 5,500 million Tablets, capsules and vials and 45,000 kgs of Bulk Drugs/API. The facility has already been approved by authorities from regulated markets like US, UK, Germany, Australia and South Africa. The manufacturing plant at Baddi has a capacity to manufacture 3,300 million tablets and 350 million capsules. The newly constructed manufacturing plant at Sikkim has a capacity to manufacture 3,900 million tablets per annum.

